LEROY BELL: Open Payments
NPI 1568434181 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,175 in 129 payments from 12 companies in 2025. Trend: 2023 $2,560 · 2024 $2,480 · 2025 $9,175
Speaker / faculty: $6,650Food & beverage: $2,403Education: $121
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $7,017 |
| Neurocrine BioSciences, Inc. | 23 | $489 |
| E.R. Squibb & Sons, L.L.C. | 18 | $410 |
| Janssen Pharmaceuticals, Inc | 10 | $257 |
| Otsuka America Pharmaceutical, Inc. | 10 | $220 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $216 |
| ABBVIE INC. | 25 | $206 |
| Alkermes, Inc. | 9 | $181 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Luye Pharma (USA) Ltd. | 2 | $46 |
Products named: UZEDY, INGREZZA, COBENFY, CAPLYTA, VRAYLAR, INVEGA SUSTENNA, ARISTADA, ABILIFY MAINTENA.
Industry payments across MD — which companies pay providers there.
